跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 4,493 条关于
“D816V mutant KIT”
全部
4,493
临床试验
2,642
药物
569
机构
52
资讯
1,230
4个月前
NICE Recommends Blueprint Medicines' Ayvakyt for Advanced Systemic Mastocytosis on NHS
去年
Cogent Bio Presents Bezuclastinib Data Highlighting Long-Term Benefits in Non-Advanced Systemic Mastocytosis
去年
Hoth Therapeutics' HT-KIT Shows Promising Preclinical Results in KIT-Driven Cancers
去年
Bezuclastinib Shows Promise in Advanced Systemic Mastocytosis Treatment
10个月前
Cogent Biosciences Unveils Promising KRAS Inhibitor Data with Superior Efficacy Profile
3个月前
Ayvakit (Avapritinib) Emerges as Targeted Therapy for Indolent Systemic Mastocytosis, Addressing Root Cause of Rare Mast Cell Disease
10个月前
Cogent Biosciences Raises $475.3 Million to Advance Bezuclastinib for Systemic Mastocytosis
前天
FDA Accepts Cogent Biosciences' NDA for Bezuclastinib in Advanced Systemic Mastocytosis, PDUFA Set for June 2027
去年
Bezuclastinib Achieves 87% Response Rate in Pivotal Trial for Non-Advanced Systemic Mastocytosis
去年
Cogent Biosciences Secures $400M Debt Financing to Advance Bezuclastinib Through Pivotal Trials
第 1 页,共 123 页
上一页
下一页